# BioGeometry

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biogeometry

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.biogeom.com
- Total disclosed funding: $110M
- Latest round: Series A (Oct 30, 2026)
- Investors on record: 13

## About

Founded in 2022 and based in Beijing, China, Beijing BioGeometry Biotechnology Co., Ltd., trading as BioGeometry, is a digital biotechnology company that specializes in applying generative AI to protein design. The company's founder, Dr. Jian Tang, is an associate professor at the Institute of Algorithms at the University of Montreal, Canada, and was a researcher at Microsoft Research Asia. The company also has partanerships with Nvidia, Intel, IBM and other companies. In June 2026, it closed a series A funding. 
The company builds TorchDrug, an open source machine learning system mainly for small molecule drug development, and TorchProtein, an open source platform for large molecule drug development, and is committed to accelerating the process of drug development through AI. The company has also built GeoFlow, a generative AI protein design macromodel that can be used for both antigen-antibody complex structure prediction and antibody design tasks. Based on this big model, the company has developed the GeoBiologics one-stop protein design platform.
The company generates revenue by providing AI-driven protein design services and licensing its proprietary platforms to pharmaceutical and biotechnology firms.
The company will use the series A funding for the further research and optimization of its AI-powered macromolecular drug design platform and high-throughput wet laboratory validation platform, accelerating the design and validation process of candidate drugs and driving more innovative drugs into the clinical stage.

## Funding rounds

- Series A, Oct 30, 2026, $100M — China Life Capital, China Life Equity, Guofang Venture Capital, Reliance Investment, Shanghai Biomedical Industry Fund, Dacheng Wealth Capital, China Development Venture Capital
- Series A, Jun 9, 2026 — Fortune Capital, CAS Investment Management, Gaorong Ventures, Index Capital, Shanghai Industrial Investment, Xinglian Capital
- Angel, Sep 21, 2022, $10M — Gaorong Ventures

## Investors

- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Angel, Series A
- Fortune Capital — Series A
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series A
- Index Capital (https://capitalatlas.ai/funds/index-capital) — Series A
- Shanghai Industrial Investment (https://capitalatlas.ai/funds/shanghai-industrial-investment) — Series A
- Xinglian Capital (https://capitalatlas.ai/funds/xinglian-capital) — Series A
- China Life Capital — Series A
- China Life Equity — Series A
- Guofang Venture Capital — Series A
- Reliance Investment — Series A
- Shanghai Biomedical Industry Fund — Series A
- Dacheng Wealth Capital — Series A
- China Development Venture Capital — Series A